100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant CE152412
Award Date
9/30/23
Completion Date
11/30/24
Dollars Obligated
$4M
Overview
Activity
11
Transactions
11
Subawards
Similar Awards
Funding Federal Agency
Healthcare Systems Bureau
Awarding Federal Agency
Office of Federal Assistance Management
Awardee
Cmit Louisiana LLC (S36QLE3ZXQM5)
Federal Grant Program
93.493
Assistance Type
Project Grant
Place of Performance
Shreveport, LA, USA
Update #1
Update #2
COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION
Posted 9/19/23
5
1
2
3
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION - ADDRESS: 2120 KINGS HIGHWAY SHREVEPORT, LA 71103 PROJECT DIRECTOR: STEPHEN LOKITZ, PHD 318-716-4006; FAX- 318-716-4120 STEPHEN.LOKITZ@CMITLA.COM WWW.CMITLA.ORG PROGRAM FUNDS REQUESTED: $2 MILLION PROJECT ABSTRACT: BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA (BRF), A 501(C)(3) NON-PROFIT IN SHREVEPORT, LOUISIANA, MANAGES SIX DIVISIONS FOCUSED ON HEALTHCARE, RESEARCH, EDUCATION, AND ECONOMIC DEVELOPMENT. BRF IS A PARENT TO CMIT LOUISIANA, LLC, THE APPLICANT. CMIT, OR THE CENTER FOR MOLECULAR IMAGING AND THERAPY, IS A RESEARCH ORGANIZATION DEVOTED TO DEVELOPING NOVEL RADIOPHARMACEUTICALS THAT CAN LEAD TO IMPROVED DIAGNOSIS AND THERAPY FOR A WIDE RANGE OF DISEASES. CMIT ACTIVELY PERFORMS RADIOPHARMACEUTICAL AND TRANSLATIONAL RESEARCH, AND CLINICAL IMAGING. IN 2022, CMIT OPENED A 23,000 SQ. FT. STATE-OF-THE-ART FACILITY TO PROMOTE MOLECULAR IMAGING AS A CATALYST TO 1) ADVANCE RESEARCH IN DISEASE DIAGNOSIS AND THERAPY, 2) INCREASE HEALTHCARE ACCESS AND QUALITY OF TREATMENTS, AND 3) PROMOTE ECONOMIC DEVELOPMENT THROUGHOUT NORTH LOUISIANA AND BEYOND. BRF INVESTED $16.4M AND RAISED $3.1M FROM PUBLIC AND PRIVATE SOURCES TO BUILD AND EQUIP THE NEW $19M FACILITY. TO FULLY MEET ITS POTENTIAL AND MISSION, CMIT IS NOW SEEKING TO ACQUIRE A NEW, STATE OF THE ART PET/CT SCANNER WITH $2M OF COMMUNITY PROJECT FUNDING. CMIT WAS ESTABLISHED AS THE FIRST POSITRON EMISSION TOMOGRAPHY (PET) IMAGING CENTER IN LOUISIANA IN 1995. THE RECENT CONSOLIDATION OF THREE FACILITIES AND UPGRADING ESSENTIAL EQUIPMENT ESTABLISHES CMIT AS ONE OF ONLY A HANDFUL OF PRIVATELY-OPERATED FACILITIES IN THE NATION WITH CAPABILITIES AND EXPERTISE TO PROVIDE COMPREHENSIVE CLINICAL CARE, BASIC AND PRE-CLINICAL RESEARCH, AND RADIOPHARMACEUTICAL METHOD OPTIMIZATION AND MANUFACTURING. CMIT PRODUCES MULTIPLE PET RADIOPHARMACEUTICALS; SUPPORTS CLINICAL AND RESEARCH EFFORTS FOR MULTIPLE DISEASES INCLUDING CANCER, CARDIAC, AND ALZHEIMER'S; AND COLLABORATES WITH EDUCATIONAL INSTITUTIONS AND PHARMACEUTICAL COMPANIES ACROSS SEVERAL STATES. THIS PROJECT WILL EXPAND CURRENT SERVICES AND CAPABILITIES BY ADVANCING RADIOPHARMACEUTICAL MANUFACTURING EXPERTISE AND TECHNOLOGY FOR CLINICAL AND RESEARCH USE, AND BY INCREASING COMPREHENSIVE BASIC AND PRECLINICAL RESEARCH TO DEVELOP NEW THERAPIES AND SUPPORT COLLABORATIONS WITH HIGHER EDUCATION AND INDUSTRY PARTNERS NATION-WIDE. WHILE CMIT CURRENTLY HAS A PET/CT SCANNER, RESEARCH SCANS, WHICH INVOLVE NOVEL PROCEDURES AND CAN BE LENGTHY AND COMPLICATED, ARE LIMITED DUE TO CMIT'S CLINICAL VOLUME. THE ADDITION OF A SECOND, HIGHLY ADVANCED SCANNER WILL ALLOW CMIT TO SIMULTANEOUSLY CONDUCT CLINICAL AND RESEARCH SCANS, SIGNIFICANTLY EXPANDING RESEARCH SCANNING VOLUME. THIS SCANNER WILL ALSO BE ATTRACTIVE TO PHARMACEUTICAL COMPANIES AND SPONSORS PERFORMING CLINICAL TRIALS AS THEY OFTEN REQUIRE THE MOST ADVANCED TECHNOLOGY TO ENSURE THEIR RESEARCH IS SUCCESSFUL. THIS WILL IN TURN PROVIDE REGIONAL ACCESS TO CUTTING-EDGE CLINICAL TRIALS THAT WOULD OTHERWISE BE CONDUCTED ELSEWHERE. THE NEW SCANNER WILL INCREASE PATIENT ACCESS TO THE MOST ADVANCED IMAGING CARE AVAILABLE IN OUR REGION AND WILL EMPOWER CLINICIANS BY PROVIDING MORE PRECISE DIAGNOSTIC INFORMATION, POTENTIALLY IMPROVING PATIENT DIAGNOSIS, TREATMENT, AND OUTCOMES. ALTHOUGH CMIT IS LOCATED IN SHREVEPORT, LOUISIANA, A CITY OF 184,021 ACCORDING TO THE U.S. CENSUS BUREAU, IT SERVES PATIENTS FROM THE SURROUNDING REGION INCLUDING MANY FROM TEXAS AND ARKANSAS. IN FISCAL YEAR (FY) 2022, 1,358 PATIENTS WERE SERVED INCLUDING THOSE RECEIVING DIAGNOSTIC AND/OR THERAPEUTIC CARE AND THOSE PARTICIPATING IN CLINICAL TRIALS. CMIT ALSO PROVIDES RADIOPHARMACEUTICALS TO 8 STATES AND EXPECTS THAT NUMBER TO INCREASE AS ITS RADIOPHARMACEUTICAL LIBRARY GROWS. CMIT ALSO SERVES A HIGH NUMBER OF INDIGENT PATIENTS, WITH 41 PERCENT OF FY2021 PATIENTS UNDERINSURED OR UNINSURED, AND MORE THAN $30 MILLION IN FREE CARE PROVIDED IN ITS HISTORY.
$0
5/23/25
Not listed
COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION - ADDRESS: 2120 KINGS HIGHWAY SHREVEPORT, LA 71103 PROJECT DIRECTOR: STEPHEN LOKITZ, PHD 318-716-4006; FAX- 318-716-4120 STEPHEN.LOKITZ@CMITLA.COM WWW.CMITLA.ORG PROGRAM FUNDS REQUESTED: $2 MILLION PROJECT ABSTRACT: BIOMEDICAL RESEARCH FOUNDATION OF NORTHWEST LOUISIANA (BRF), A 501(C)(3) NON-PROFIT IN SHREVEPORT, LOUISIANA, MANAGES SIX DIVISIONS FOCUSED ON HEALTHCARE, RESEARCH, EDUCATION, AND ECONOMIC DEVELOPMENT. BRF IS A PARENT TO CMIT LOUISIANA, LLC, THE APPLICANT. CMIT, OR THE CENTER FOR MOLECULAR IMAGING AND THERAPY, IS A RESEARCH ORGANIZATION DEVOTED TO DEVELOPING NOVEL RADIOPHARMACEUTICALS THAT CAN LEAD TO IMPROVED DIAGNOSIS AND THERAPY FOR A WIDE RANGE OF DISEASES. CMIT ACTIVELY PERFORMS RADIOPHARMACEUTICAL AND TRANSLATIONAL RESEARCH, AND CLINICAL IMAGING. IN 2022, CMIT OPENED A 23,000 SQ. FT. STATE-OF-THE-ART FACILITY TO PROMOTE MOLECULAR IMAGING AS A CATALYST TO 1) ADVANCE RESEARCH IN DISEASE DIAGNOSIS AND THERAPY, 2) INCREASE HEALTHCARE ACCESS AND QUALITY OF TREATMENTS, AND 3) PROMOTE ECONOMIC DEVELOPMENT THROUGHOUT NORTH LOUISIANA AND BEYOND. BRF INVESTED $16.4M AND RAISED $3.1M FROM PUBLIC AND PRIVATE SOURCES TO BUILD AND EQUIP THE NEW $19M FACILITY. TO FULLY MEET ITS POTENTIAL AND MISSION, CMIT IS NOW SEEKING TO ACQUIRE A NEW, STATE OF THE ART PET/CT SCANNER WITH $2M OF COMMUNITY PROJECT FUNDING. CMIT WAS ESTABLISHED AS THE FIRST POSITRON EMISSION TOMOGRAPHY (PET) IMAGING CENTER IN LOUISIANA IN 1995. THE RECENT CONSOLIDATION OF THREE FACILITIES AND UPGRADING ESSENTIAL EQUIPMENT ESTABLISHES CMIT AS ONE OF ONLY A HANDFUL OF PRIVATELY-OPERATED FACILITIES IN THE NATION WITH CAPABILITIES AND EXPERTISE TO PROVIDE COMPREHENSIVE CLINICAL CARE, BASIC AND PRE-CLINICAL RESEARCH, AND RADIOPHARMACEUTICAL METHOD OPTIMIZATION AND MANUFACTURING. CMIT PRODUCES MULTIPLE PET RADIOPHARMACEUTICALS; SUPPORTS CLINICAL AND RESEARCH EFFORTS FOR MULTIPLE DISEASES INCLUDING CANCER, CARDIAC, AND ALZHEIMER'S; AND COLLABORATES WITH EDUCATIONAL INSTITUTIONS AND PHARMACEUTICAL COMPANIES ACROSS SEVERAL STATES. THIS PROJECT WILL EXPAND CURRENT SERVICES AND CAPABILITIES BY ADVANCING RADIOPHARMACEUTICAL MANUFACTURING EXPERTISE AND TECHNOLOGY FOR CLINICAL AND RESEARCH USE, AND BY INCREASING COMPREHENSIVE BASIC AND PRECLINICAL RESEARCH TO DEVELOP NEW THERAPIES AND SUPPORT COLLABORATIONS WITH HIGHER EDUCATION AND INDUSTRY PARTNERS NATION-WIDE. WHILE CMIT CURRENTLY HAS A PET/CT SCANNER, RESEARCH SCANS, WHICH INVOLVE NOVEL PROCEDURES AND CAN BE LENGTHY AND COMPLICATED, ARE LIMITED DUE TO CMIT'S CLINICAL VOLUME. THE ADDITION OF A SECOND, HIGHLY ADVANCED SCANNER WILL ALLOW CMIT TO SIMULTANEOUSLY CONDUCT CLINICAL AND RESEARCH SCANS, SIGNIFICANTLY EXPANDING RESEARCH SCANNING VOLUME. THIS SCANNER WILL ALSO BE ATTRACTIVE TO PHARMACEUTICAL COMPANIES AND SPONSORS PERFORMING CLINICAL TRIALS AS THEY OFTEN REQUIRE THE MOST ADVANCED TECHNOLOGY TO ENSURE THEIR RESEARCH IS SUCCESSFUL. THIS WILL IN TURN PROVIDE REGIONAL ACCESS TO CUTTING-EDGE CLINICAL TRIALS THAT WOULD OTHERWISE BE CONDUCTED ELSEWHERE. THE NEW SCANNER WILL INCREASE PATIENT ACCESS TO THE MOST ADVANCED IMAGING CARE AVAILABLE IN OUR REGION AND WILL EMPOWER CLINICIANS BY PROVIDING MORE PRECISE DIAGNOSTIC INFORMATION, POTENTIALLY IMPROVING PATIENT DIAGNOSIS, TREATMENT, AND OUTCOMES. ALTHOUGH CMIT IS LOCATED IN SHREVEPORT, LOUISIANA, A CITY OF 184,021 ACCORDING TO THE U.S. CENSUS BUREAU, IT SERVES PATIENTS FROM THE SURROUNDING REGION INCLUDING MANY FROM TEXAS AND ARKANSAS. IN FISCAL YEAR (FY) 2022, 1,358 PATIENTS WERE SERVED INCLUDING THOSE RECEIVING DIAGNOSTIC AND/OR THERAPEUTIC CARE AND THOSE PARTICIPATING IN CLINICAL TRIALS. CMIT ALSO PROVIDES RADIOPHARMACEUTICALS TO 8 STATES AND EXPECTS THAT NUMBER TO INCREASE AS ITS RADIOPHARMACEUTICAL LIBRARY GROWS. CMIT ALSO SERVES A HIGH NUMBER OF INDIGENT PATIENTS, WITH 41 PERCENT OF FY2021 PATIENTS UNDERINSURED OR UNINSURED, AND MORE THAN $30 MILLION IN FREE CARE PROVIDED IN ITS HISTORY.
$0
12/13/24
Not listed
COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION
$0
12/13/24
Not listed
COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION
$0
11/16/23
Not listed
COMMUNITY PROJECT FUNDING/CONGRESSIONALLY DIRECTED SPENDING - CONSTRUCTION
$0
11/16/23